232 related articles for article (PubMed ID: 34902760)
1. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
2. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Baker D; Pryce G; James LK; Marta M; Schmierer K
Mult Scler Relat Disord; 2020 Sep; 44():102279. PubMed ID: 32645640
[TBL] [Abstract][Full Text] [Related]
3. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
Alroughani R; Al-Hashel J; Ahmed SF
Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
5. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
[TBL] [Abstract][Full Text] [Related]
6. Both cladribine and alemtuzumab may effect MS via B-cell depletion.
Baker D; Herrod SS; Alvarez-Gonzalez C; Zalewski L; Albor C; Schmierer K
Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e360. PubMed ID: 28626781
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
8. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
[TBL] [Abstract][Full Text] [Related]
9. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
Gabelić T; Barun B; Adamec I; Krbot Skorić M; Habek M
Hum Vaccin Immunother; 2021 Nov; 17(11):4345-4362. PubMed ID: 34668842
[TBL] [Abstract][Full Text] [Related]
10. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
11. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S
Front Immunol; 2023; 14():1254128. PubMed ID: 37841269
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Śladowska K; Kawalec P; Holko P; Osiecka O
Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
Buttari F; Bruno A; Dolcetti E; Azzolini F; Bellantonio P; Centonze D; Fantozzi R
Mult Scler Relat Disord; 2021 Jul; 52():102983. PubMed ID: 33990054
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
[TBL] [Abstract][Full Text] [Related]
15. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
Tazza F; Lapucci C; Cellerino M; Boffa G; Novi G; Poire I; Mancuso E; Bruschi N; Sbragia E; Laroni A; Capello E; Inglese M
J Neurol Sci; 2021 Aug; 427():117501. PubMed ID: 34044238
[TBL] [Abstract][Full Text] [Related]
16. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
Georgieva ZG; Dӧffinger R; Kumararatne D; Coles AJ; McCarthy C
Mult Scler; 2022 Jun; 28(7):1126-1130. PubMed ID: 34595965
[TBL] [Abstract][Full Text] [Related]
17. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
18. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
Adamec I; Habek M
Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
[TBL] [Abstract][Full Text] [Related]
20. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]